BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 317654)

  • 1. [Immunotherapeutic possibilities for treatment of malignant melanomas].
    Kokoschka EM
    Hautarzt; 1979 Dec; 30(12):656-61. PubMed ID: 317654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development in the immunotherapy of malignant melanoma].
    Tritsch H
    Hautarzt; 1976 Jan; 27(1):1-7. PubMed ID: 767300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A malignus melanoma immunterápiájának lehetoségei].
    Ladányi A
    Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possibilities of immunotherapy and gene therapy for malignant melanoma.
    Crowley NJ; Seigler HF
    Semin Surg Oncol; 1993; 9(3):273-8. PubMed ID: 8516616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
    Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; Liénard D; Lejeune F; Cerottini JC; Romero P
    Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Possibilities of immunotherapy in malignant melanoma].
    Lewis MG
    Hautarzt; 1978 Dec; 29(12):619-24. PubMed ID: 363650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for melanoma.
    Komenaka I; Hoerig H; Kaufman HL
    Clin Dermatol; 2004; 22(3):251-65. PubMed ID: 15262312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current immunotherapeutic strategies in malignant melanoma.
    Agostino NM; Ali A; Nair SG; Mosca PJ
    Surg Oncol Clin N Am; 2007 Oct; 16(4):945-73, xi. PubMed ID: 18022553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapeutic approaches for the treatment of malignant melanoma.
    Curiel-Lewandrowski C; Atkins MB
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1553-63. PubMed ID: 11763157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
    Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
    Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma-associated tumor antigens and their clinical relevance to immunotherapy.
    Gattoni-Celli S; Cole DJ
    Semin Oncol; 1996 Dec; 23(6):754-8. PubMed ID: 8970598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy of melanoma.
    Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
    Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Local immunotherapy. Alternative therapy for malignant cutaneous lesions (demonstration on 30 patients with malignant melanoma) (author's transl)].
    Kokoschka EM; Micksche M
    Wien Klin Wochenschr; 1979 Mar; 91(5):150-4. PubMed ID: 425533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell-based immunotherapy of melanoma: what have we learned and how can we improve?
    Campoli M; Ferrone S
    Expert Rev Vaccines; 2004 Apr; 3(2):171-87. PubMed ID: 15056043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.
    Mittelman A; Chen ZJ; Liu CC; Hirai S; Ferrone S
    Cancer Res; 1994 Jan; 54(2):415-21. PubMed ID: 8275478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunotherapy of malignant melanoma--basic principles and novel therapeutic approaches].
    Enk AH; Becker JC; Schuler G
    J Dtsch Dermatol Ges; 2006 Aug; 4(8):635-45. PubMed ID: 16895565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
    Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
    Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen-specific cultured T cells can mediate tumor therapy and provide long-term immunologic memory in vivo.
    Cheever MA; Klarnet JP; Peace DJ; Greenberg PD
    Prog Clin Biol Res; 1987; 244():49-58. PubMed ID: 3498958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?
    Tietze JK; Sckisel GD; Hsiao HH; Murphy WJ
    Int Rev Immunol; 2011; 30(5-6):238-93. PubMed ID: 22053969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunology and therapy of malignant melanoma (author's transl)].
    Kokoschka EM; Micksche M
    Wien Klin Wochenschr; 1977 Sep; 89(18):612-22. PubMed ID: 906525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.